Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. 1981

K Landmark, and J E Bredesen, and E Thaulow, and S Simonsen, and J P Amlie

The parmacokinetics of disopyramide (DP) in 10 patients with imminent to moderate cardiac failure has been studied and compared with the results in normal volunteers. The biological half life of rapid distribution (T1/2 alpha) and of elimination (T1/2 beta) were increased (11.1 +/- 4.4 min and 9.7 +/- 4.2 h, respectively). Total body clearance (Clt) was decreased (0.467 +/- 0.215 ml . min-1 . kg-1), and the volume of distribution (Vd) was slightly reduced (0.610 +/- 0.1361 . kg-1), probably due to the lower cardiac index. After oral administration, the time of peak serum concentration was increased (139 +/- 89 min), and the mean peak serum concentration (2.4 +/- 0.8% dose . 1-1) was also higher than reported in normal subjects. Comparison of the areas under the concentration versus time curves after intravenous and oral administration (AUC i. v. and AUC oral) showed that DP was almost completely absorbed, its bioavailability being 97.5 +/- 15.0%.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D004206 Disopyramide A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. Diisopyramide,Disopyramide Monohydrochloride,Disopyramide Phosphate,Disopyramide Phosphate (1:1),Disopyramide Phosphate (1:1), (+-)-Isomer,Disopyramide Phosphate (1:1), (R)-Isomer,Disopyramide Phosphate (1:1), (S)-Isomer,Disopyramide, (+-)-Isomer,Disopyramide, (R)-Isomer,Disopyramide, (S)-Isomer,Disopyramide, D-Tartrate (1:1), (S)-Isomer,Disopyramide, L-Tartrate (1:1), (R)-Isomer,Disopyramide, L-Tartrate (1:1), (S)-Isomer,Disopyramide, L-Tartrate (1:2), (+-)-Isomer,Disopyramide, L-Tartrate, (S)-isomer,Norpace,Palpitin,Palpitine,Rhythmodan,Ritmilen,Rythmilen,SC-13957,SC 13957,SC13957
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

K Landmark, and J E Bredesen, and E Thaulow, and S Simonsen, and J P Amlie
January 1983, European journal of drug metabolism and pharmacokinetics,
K Landmark, and J E Bredesen, and E Thaulow, and S Simonsen, and J P Amlie
April 1988, Journal of clinical pharmacology,
K Landmark, and J E Bredesen, and E Thaulow, and S Simonsen, and J P Amlie
May 1991, Nihon Jinzo Gakkai shi,
K Landmark, and J E Bredesen, and E Thaulow, and S Simonsen, and J P Amlie
January 1976, Clinical pharmacokinetics,
K Landmark, and J E Bredesen, and E Thaulow, and S Simonsen, and J P Amlie
January 1985, European journal of clinical pharmacology,
K Landmark, and J E Bredesen, and E Thaulow, and S Simonsen, and J P Amlie
April 1979, British journal of clinical pharmacology,
K Landmark, and J E Bredesen, and E Thaulow, and S Simonsen, and J P Amlie
July 2000, American heart journal,
K Landmark, and J E Bredesen, and E Thaulow, and S Simonsen, and J P Amlie
September 1980, British journal of clinical pharmacology,
K Landmark, and J E Bredesen, and E Thaulow, and S Simonsen, and J P Amlie
June 1982, International journal of clinical pharmacology, therapy, and toxicology,
K Landmark, and J E Bredesen, and E Thaulow, and S Simonsen, and J P Amlie
February 1981, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!